Galectin Therapeutics Inc.
http://www.galectintherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Galectin Therapeutics Inc.
Analysts Impressed By Amryt As EB Drug Action Date Approaches
Amryt has set out its future plans to the investment community with much depending on the successful relaunch of its just-acquired acromegaly drug Mycapssa and a potential FDA approval for its epidermolysis bullosa gel Filsuvez.
Gilead’s Long-Acting HIV Drug Among Latest EU Filings
The European Medicines Agency has added seven new products to its list of medicines that are under review for potential EU marketing authorization.
Mobocertinib, Asciminib & Surufatinib Among Latest New Filings In EU
The European Medicines Agency has added nine new products to its latest list of medicines that are under review for potential EU marketing authorization.
Orphan Drugs Nefecon, Maribavir & Copanlisib Among New EU Filings
Marketing applications for two generic versions of the multiple sclerosis blockbuster, Tecfidera, are also under review by the European Medicines Agency.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Other Names / Subsidiaries
-
- Galectin Sciences, LLC
- Pro-Pharmaceuticals Inc.
- Galectin Therapeutics Security Corp.